Anti-tumor efficacy of hyaluronan-based nanoparticles for the co-delivery of drugs in lung cancer

Victor Jeannot(Bracco (Switzerland)), Amandine Hurbin(Agir Pour les Maladies Chroniques)

Journal of Controlled Release

February 20, 2018

10.1016/j.jconrel.2018.02.024

Cited by 88

Related Papers

The PI3K/AKT pathway promotes gefitinib resistance in mutant <i>KRAS</i> lung adenocarcinoma by a deacetylase‐dependent mechanism

|International Journal of Cancer|2013|57

Synergistic activity of vorinostat combined with gefitinib but not with sorafenib in mutant KRAS human non-small cell lung cancers and hepatocarcinoma

|OncoTargets and Therapy|2016|36

The pyrrolopyrimidine colchicine-binding site agent PP-13 reduces the metastatic dissemination of invasive cancer cells in vitro and in vivo

|Biochemical Pharmacology|2018|17